In this double-blind, randomized, placebo-controlled, international study, researchers assessed the effectiveness and safety of pregabalin as adjunctive treatment for children (aged 4-16 years) with partial-onset seizures, termed focal onset seizures for this investigation. The criteria for selection included focal onset seizures and a stable regimen of 1 to 3 antiepileptic drugs. Pregabalin 2.5 mg/kg/d, 10 mg/kg/d or placebo were used in the study, with doses increased to 3.5 or 14 mg/kg/d for subjects weighing <30 kg. According to findings, pregabalin 10 mg/kg/d was effective in reducing the seizure frequency in children with focal onset seizures vs placebo, and both doses of pregabalin were generally safe and well tolerated. Common adverse events included somnolence, increased weight and increased appetite.
March 25, 2020
Study Finds Pregabalin (Lyrica®) Adjunctive Therapy Significantly Reduces Seizure Rate in Children One Month to Over Four Years with Focal Onset Seizures
Pregabalin 14 mg/kg/d (but not 7 mg/kg/d) significantly reduced seizure rate in children with focal-onset seizures, when assessed using V?EEG, compared with placebo.
March 24, 2020
Study Finds Levetiracetam Not Significantly Better Than Phenytoin in Ending Seizures in Patients with Established Status Epilepticus
Moderate-quality evidence suggested that levetiracetam was not significantly superior to phenytoin in seizure cessation in patients with established status epilepticus.